But biomarker enrichment and toxicity remain key for FX-909.
ApexOnco Front Page
Recent articles
The month saw the first commissioner's priority voucher approval in oncology.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
The group is expanding its mRNA-4359 trial to include first-line melanoma.
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
